Physician profile
Hareth Raddawi
NPI 1063440535
$2,021.71
in general payments reported to CMS, 2019-2025
18 companies · $332 in 2025
The $332 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2021: $212 · 2022: $186 · 2023: $862 · 2024: $171 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,364.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $702.69 | 2019-2023 | |
| Qol Medical, LLC | $256.61 | 2023-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $166.67 | 2019-2024 | Entyvio, Gattex |
| Medical Device Business Services, INC. | $148.43 | 2019 | |
| Intuitive Surgical, INC. | $132.80 | 2025 | |
| Aimmune Therapeutics, INC. | $125.00 | 2025 | Zenpep |
| Redhill Biopharma INC. | $95.76 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.99 | 2023 | Xifaxan |
| Pfizer INC. | $59.57 | 2023 | |
| Janssen Biotech, INC. | $51.90 | 2023 | Stelara, Simponi, Simponi Aria |
| Celgene Corporation | $39.59 | 2023 | Zeposia |
| Ardelyx, INC. | $32.83 | 2023 | Ibsrela |
| Conmed Corporation | $27.27 | 2024 | Conmed Biliary |
| Lilly USA, LLC | $25.02 | 2024 | Omvoh |
| Ironwood Pharmaceuticals, INC | $24.90 | 2023 | Linzess |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $20.61 | 2025 | Vegzelma |
| Vivus LLC | $19.07 | 2023 | Pancreaze |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$7,775.24 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hareth Raddawi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.